Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HUTCHMED Announces That The New Drug Application For TAZVERIK (tazemetostat) Has Been Granted Conditional Approval In China For The Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma With EZH2 Mutation Who Have Received At Least Two Prior Systemic Therapies

Author: Benzinga Newsdesk | March 21, 2025 06:03am

Posted In: HCM